141 related articles for article (PubMed ID: 28658406)
21. Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1.
Hwang IK; Hahn SM; Kim HS; Kim SK; Kim HS; Shin KH; Suh CO; Lyu CJ; Han JW
Cancer Res Treat; 2017 Jul; 49(3):717-726. PubMed ID: 28052660
[TBL] [Abstract][Full Text] [Related]
22. Malignant triton tumors--complete surgical resection and adjuvant radiotherapy associated with improved survival.
McConnell YJ; Giacomantonio CA
J Surg Oncol; 2012 Jul; 106(1):51-6. PubMed ID: 22253011
[TBL] [Abstract][Full Text] [Related]
23. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
24. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience.
Stucky CC; Johnson KN; Gray RJ; Pockaj BA; Ocal IT; Rose PS; Wasif N
Ann Surg Oncol; 2012 Mar; 19(3):878-85. PubMed ID: 21861229
[TBL] [Abstract][Full Text] [Related]
25. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
[TBL] [Abstract][Full Text] [Related]
27. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
[TBL] [Abstract][Full Text] [Related]
28. Benign-appearing Intraspinal Malignant Peripheral Nerve Sheath Tumors: Treatments and Outcomes of 14 Consecutive Patients.
Gong H; Zhang D; Wang D; He S; Yang X; Wei H; Xiao J
Turk Neurosurg; 2018; 28(6):983-988. PubMed ID: 29634079
[TBL] [Abstract][Full Text] [Related]
29. Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Hirbe AC; Dehner CA; Dombi E; Eulo V; Gross AM; Sundby T; Lazar AJ; Widemann BC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432242. PubMed ID: 38710002
[TBL] [Abstract][Full Text] [Related]
30. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
[TBL] [Abstract][Full Text] [Related]
31. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
Danielsen SA; Lind GE; Kolberg M; Høland M; Bjerkehagen B; Sundby Hall K; van den Berg E; Mertens F; Smeland S; Picci P; Lothe RA
Neuro Oncol; 2015 Jan; 17(1):63-9. PubMed ID: 25038505
[TBL] [Abstract][Full Text] [Related]
32. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years.
Ingham S; Huson SM; Moran A; Wylie J; Leahy M; Evans DG
Eur J Cancer; 2011 Dec; 47(18):2723-8. PubMed ID: 21700447
[TBL] [Abstract][Full Text] [Related]
33. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
Ferner RE; Gutmann DH
Cancer Res; 2002 Mar; 62(5):1573-7. PubMed ID: 11894862
[TBL] [Abstract][Full Text] [Related]
34. Malignant peripheral nerve sheath tumor: analysis of treatment outcome.
Wong WW; Hirose T; Scheithauer BW; Schild SE; Gunderson LL
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):351-60. PubMed ID: 9788415
[TBL] [Abstract][Full Text] [Related]
35. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?
Gladdy RA; Qin LX; Moraco N; Edgar MA; Antonescu CR; Alektiar KM; Brennan MF; Singer S
J Clin Oncol; 2010 Apr; 28(12):2064-9. PubMed ID: 20308666
[TBL] [Abstract][Full Text] [Related]
36. Malignant peripheral nerve sheath tumor with analysis of various prognostic factors: A single-institutional experience.
Sharma MR; Puj KS; Salunke AA; Pandya SJ; Gandhi JS; Parikh AR
J Cancer Res Ther; 2021; 17(1):106-113. PubMed ID: 33723140
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
38. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs).
Upadhyaya M; Spurlock G; Majounie E; Griffiths S; Forrester N; Baser M; Huson SM; Gareth Evans D; Ferner R
Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786508
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
40. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group.
Brekke HR; Ribeiro FR; Kolberg M; Agesen TH; Lind GE; Eknaes M; Hall KS; Bjerkehagen B; van den Berg E; Teixeira MR; Mandahl N; Smeland S; Mertens F; Skotheim RI; Lothe RA
J Clin Oncol; 2010 Mar; 28(9):1573-82. PubMed ID: 20159821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
